Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1300 of 3284 entries
View as:

SABINA INTERNATIONAL

Phase: N/A Priority: Normal
NCT ID: NCT03857178 Org: User:
Start: 03/29/19 End: 05/06/20 Due: 05/06/21

The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil

Phase: N/A Priority: Normal
NCT ID: NCT01024660 Org: User:
Start: 12/31/09 End: 01/31/11 Due: 01/31/12

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Phase: N/A Priority: Normal
NCT ID: NCT00441727 Org: User:
Start: 02/28/07 End: 08/31/08 Due: 08/31/09

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06103864 Org: User:
Start: 11/23/23 End: 03/26/31 Due: 03/26/32

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

Phase: N/A Priority: Normal
NCT ID: NCT02640755 Org: User:
Start: 01/28/16 End: 07/06/17 Due: 07/06/18

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00714337 Org: User:
Start: 06/30/08 End: 08/31/08 Due: 08/31/09

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Phase: N/A Priority: Normal
NCT ID: NCT04960709 Org: User:
Start: 08/05/21 End: 09/08/28 Due: 09/08/29

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02392676 Org: User:
Start: 07/31/16 End: 06/30/19 Due: 06/30/20

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Phase: N/A Priority: Normal
NCT ID: NCT05569421 Org: User:
Start: 10/11/22 End: 04/14/23 Due: 04/14/24

Oxis 9mcg Turbuhaler Clinical Experience Investigation

Phase: N/A Priority: Normal
NCT ID: NCT01749462 Org: User:
Start: 02/28/13 End: 07/31/15 Due: 07/31/16

CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)

Phase: N/A Priority: Normal
NCT ID: NCT00681122 Org: User:
Start: 05/31/08 End: 05/31/11 Due: 05/31/12

A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00736606 Org: User:
Start: 08/31/08 End: 09/30/08 Due: 09/30/09

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Phase: N/A Priority: Normal
NCT ID: NCT00910728 Org: User:
Start: 05/31/09 End: 08/31/14 Due: 08/31/15

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT04949425 Org: User:
Start: 09/13/21 End: 04/21/22 Due: 04/21/23

Fast Titration Of Quetiapine Versus Currently Approved Titration

Phase: N/A Priority: Normal
NCT ID: NCT00254813 Org: User:
Start: 10/31/04 End: 09/30/05 Due: 09/30/06

Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01491412 Org: User:
Start: 12/31/11 End: 05/31/12 Due: 05/31/13

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Phase: N/A Priority: Normal
NCT ID: NCT00516438 Org: User:
Start: 07/31/07 End: 11/30/09 Due: 11/30/10

A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00772733 Org: User:
Start: 10/31/08 End: 12/31/10 Due: 12/31/11

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

Phase: N/A Priority: Normal
NCT ID: NCT06675175 Org: User:
Start: 12/16/24 End: 08/08/25 Due: 08/08/26

Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00707707 Org: User:
Start: 09/15/08 End: 02/19/18 Due: 02/19/19

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Phase: N/A Priority: Normal
NCT ID: NCT00728780 Org: User:
Start: 08/31/08 End: - Due: -

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

Phase: N/A Priority: Normal
NCT ID: NCT04208620 Org: User:
Start: 01/21/20 End: 07/08/20 Due: 07/08/21

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Phase: N/A Priority: Normal
NCT ID: NCT00806754 Org: User:
Start: 11/30/06 End: 08/31/07 Due: 08/31/08

Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00501111 Org: User:
Start: 07/31/07 End: 08/31/08 Due: 08/31/09

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT01838499 Org: User:
Start: 05/31/13 End: 10/31/14 Due: 10/31/15